Business UpdateJul 14, 2026, 07:31 AM
Plus Therapeutics CNSide Aligns with Updated NCCN Guidelines
AI Summary
Plus Therapeutics highlighted that its CNSide CSF assay platform aligns with the updated NCCN Clinical Practice Guidelines for Central Nervous System Cancers, reinforcing the value of sensitive CSF-based tools for diagnosing and monitoring leptomeningeal metastases. The company's CNSide platform has expanded its U.S. commercial foundation, achieving approximately 126 million contracted covered lives, including new agreements with Blue Shield of California and Elevance Health. Plus Therapeutics also announced it will change its corporate name to Cerenome, Inc. and trade under the Nasdaq ticker CNSY effective August 3, 2026.
Key Highlights
- NCCN Guidelines updated for CNS Cancers, reinforcing CSF analysis for LM diagnosis.
- CNSide platform designed for LM diagnosis, treatment monitoring, and management.
- CNSide data showed more than double sensitivity vs. conventional cytology in LM.
- CNSide expanded U.S. commercial coverage to approximately 126 million lives.
- New payer coverage includes Blue Shield of California and Elevance Health.
- Company's 2026 objective: 150 million covered lives and 1,250 CNSide tests.
- Plus Therapeutics to rebrand as Cerenome, Inc. and trade as CNSY from August 3, 2026.
- CNSide may reduce LM-related healthcare costs by approximately 40%.
Price Impact
More from PSTV